What changed
Summit reported $629.8 million in cash and investments as of September 30, 2026, and received $2.0 billion from AstraZeneca in connection with an equity investment after the third quarter closed. The filing discloses no revenue, EPS, or guidance figures. Over 5,000 patients have been treated with ivonescimab in clinical studies globally, and over 100,000 patients have been treated in the commercial setting in China. Akeso's Phase III studies showed statistically significant overall survival benefits for ivonescimab regimens versus pembrolizumab in PD-L1-positive advanced NSCLC and versus durvalumab plus chemotherapy in biliary tract cancer.
Why it matters
Summit reported $629.8 million in cash and investments as of September 30, 2026, and received $2.0 billion from AstraZeneca in connection with an equity investment after the third quarter closed. The